Is NVIDIA a Future Blue Chip Stock?
/
Date16 Feb 2017
The term “blue chip stock” carries a connotation of stability, safety, and often a laudable history of profit growth and steadily increasing dividends. If you... Read More →
Grupo Hotelero Santa Fe anuncia la adquisición de 933 cuartos en Los Cabos y Nuevo Vallarta
/
Date16 Feb 2017
CIUDAD DE MÉXICO, Feb. 15, 2017 (GLOBE NEWSWIRE) — Grupo Hotelero Santa Fe, S.A.B. de C.V. (BMV:HOTEL) (“HOTEL” o “la Compañía”), una de las empresas... Read More →
Castlight Health Announces Fourth Quarter and Full Year 2016 Results
/
Date16 Feb 2017
Total Revenue of $101.7 Million for the Year, Up 35% Y-o-Y Record High Gross Margin and $1.7M Cash Used in Operations in 4Q 2016 Jiff... Read More →
Rush Enterprises, Inc. Reports Fourth Quarter and Year-End 2016 Results
/
Date16 Feb 2017
Revenues of $4.2 billion, $40.6 million net income Heavy-Duty new commercial vehicle sales challenged by decreased activity from large fleets and low used truck valuations... Read More →
Laredo Petroleum Announces 2016 Fourth-Quarter and Full-Year Financial and Operating Results
/
Date16 Feb 2017
TULSA, OK, Feb. 15, 2017 (GLOBE NEWSWIRE) — Laredo Petroleum, Inc. (NYSE:LPI) (“Laredo” or the “Company”) today announced its 2016 fourth-quarter and full-year results. For... Read More →
Data Presented at CROI Show CytoDyn’s Pro 140 as a Single Agent Provided Maximal Virologic Suppression in HIV Patients for Nearly Two Years
/
Date16 Feb 2017
VANCOUVER, Washington, Feb. 15, 2017 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human... Read More →
Avis Budget Group Reports Fourth Quarter and Full-Year 2016 Results
/
Date16 Feb 2017
Revenue declined 1% in the fourth quarter, to $1.9 billion. Net loss was $31 million, and Adjusted EBITDA was $121 million in the fourth quarter.... Read More →
Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium™ 2017
/
Date16 Feb 2017
Biomarkers of Muscle Damage (AST, ALT and CK) Demonstrate Improving Trends in Majority of Patients Biomarker of Key Disease Substrate (Hex4) Demonstrates Improving Trend in... Read More →
Marathon Oil Reports Fourth Quarter and Full Year 2016 Results
/
Date16 Feb 2017
HOUSTON, Feb. 15, 2017 (GLOBE NEWSWIRE) — Marathon Oil Corporation (NYSE:MRO) today reported a full-year 2016 net loss of $2,140 million, or $2.61 per diluted... Read More →